Adaptive Biotechnologies Corpor (ADPT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.05: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.33; Below-average business quality; Negative price momentum.
Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM business licensing immune receptor data to biopharma partners. Total revenue was $277M in 2025, driven by 105,587 clonoSEQ tests (46% growth) and 180+ active... Read more
Sell if holding. Engine safety override at $14.05: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.33; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 63. Score 5.7/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierIllumina10-K Item 1A: 'Illumina supplies us with reagents that have been designed for use solely with these sequencers and Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System and the NovaSeq X Plus System.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.05: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.33; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $13.08. Score 5.7/10, moderate confidence.
Take-profit target: $17.90 (+27.3% upside). Prior stop was $13.08. Stop-loss: $13.08.
Concentration risk — Supplier: Illumina; Risk below floor (3.0 < 3.0).
Adaptive Biotechnologies Corpor trades at a P/E of N/A (forward -50.4). TrendMatrix value score: 7.4/10. Verdict: Sell.
14 analysts cover ADPT with a consensus score of 4.2/5. Average price target: $21.
What does Adaptive Biotechnologies Corpor do?Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM...
Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM business licensing immune receptor data to biopharma partners. Total revenue was $277M in 2025, driven by 105,587 clonoSEQ tests (46% growth) and 180+ active biopharma trials. Illumina is the sole provider of sequencers, reagents, and maintenance services for its lab operations.